Adverse events following immunization during COVID-19 mass

vaccination campaigns in the Democratic Republic of Congo:

Findings from active safety surveillance

- 4 Kizito Kayumba^{1*}, Alemayehu Duga¹, Mosoka Papa Fallah¹, Claire Tshidibi², Nicky Lubaki²,
- 5 Barnabas Coulibaly¹, Benjamin Djoudalbaye¹, Efire Nora Sylvana¹, Elizabeth Gonese¹, Senga
- 6 Lucy Sembuche¹, Tedi Tilahun¹, Murtala Jibril¹, Carlos Kilowe¹, Aminu Kuba¹, Antoine Mafwila
- 7 Lusala¹, Nebiyu Dereje¹, Nicaise Ndembi¹, Tajudeen Raji¹, Ngashi Ngongo¹
- 9 Affiliations

1

2

3

8

12

15

- 10 ¹Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia
- ²Ministry of Health, Kinshasa, Democratic Republic of Congo
- * Corresponding author
- 14 E-mail: KizitoK@africacdc.org (KK)
- 16 Contributorship
- 17 "KK and AD are Joint First Authors"

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Abstract Introduction: Post-marketing safety surveillance is indispensable for ensuring safety and public trust in vaccines, particularly in African settings where evidence of COVID-19 vaccine safety is less documented. We aimed to identify the types of adverse events following immunization (AEFIs), the overall incidence, and factors associated with AEFIs during mass vaccination campaigns in The Democratic Republic of Congo (DRC). Methods: From December 1 to 29, 2023, a prospective safety surveillance study was conducted on 4,766 individuals in Kinshasa Province in DRC. They were surveyed through phone calls from day 1 to 28 following the administration of the COVID-19 vaccine. We calculated AEFI incidence rates by type of vaccine, sex, and age group. We identified factors associated with AEFIs using multivariable logistic regression models, which were expressed by adjusted odds ratio (aOR) and its 95% confidence interval (CI). Results: A total of 4766 participants were included in the study. The median age of the participants was 36 years, with an interquartile range of 27 to 48 years and 2503 (53%) were females. Most of the participants (94.6%) received the Johnson & Johnson (J&J) vaccine, while 256 (5.4%) received the Pfizer vaccine. Nearly a quarter of participants (23.75%, 95% CI: 22.54%-24.99%) reported AEFIs. The most common AEFIs reported were fever (9.61%, 95%CI: 8.88%-10.48%), injection site pain (9.00%, 95%CI: 8.20%-9.85%), headache (4.11%, 95%CI: 3.57%-4.72%), stiffness (1.51%, 95%CI: 1.18%-1.89 %) and myalgia (1.15%, 95%CI: 0.87%-1.49%). The

incidence of AEFIs was higher for the Pfizer vaccine at 34.48% (95% CI: 28.57%-40.54%) compared

41 to 23.15% (95% CI: 21.92%-24.41%) for the J&J vaccine. Participants aged 36 years and above

were associated with increased odds of reporting any adverse event (aOR=1.17, 95%CI: 1.02-

1.33), injection site pain (aOR=1.36, 95% CI: 1.11-1.66), and two or more signs (aOR=1.46, 95%CI:

1.10-1.94), compared to those below 36 years of age.

Conclusions: AEFI reported by about a quarter of participants and its association with vaccine

type and older age underscores the need for systematic vaccine safety monitoring in the

population. This is critical for developing future vaccination strategies tailored to individuals

more susceptible to AEFIs.

49 Keywords: COVID-19 vaccines, Safety surveillance, Pharmacovigilance, Adverse Event

Following Immunization, The Democratic Republic of Congo, Africa CDC, Mass Vaccination

51 Campaign.

42

43

44

45

46

47

48

50

52

53

54

55

56

57

58

59

60

Introduction

Vaccines approved for use in national immunization programmes (NIPs) are considered safe and

efficacious based on verifiable evidence from randomized controlled clinical trials (RCTs)¹. These

trials provide robust evidence supporting their safety and effectiveness. However, despite the

rigorous evaluation during clinical development, it is important to note that rare side effects may

not be detected in the early phases of clinical trials. Post-marketing safety surveillance after

introducing the COVID-19 vaccine into public immunization programs must identify rare and

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

previously undocumented adverse events (AEs) to address this. For instance, the non-replicating vector COVID-19 vaccines such as AstraZeneca and Johnson & Johnson have been associated with central venous sinus and other large vessel thrombosis (~4 per million vaccinations) and thrombocytopenia. ² Similarly, messenger RNA COVID-19 vaccines have also observed rare side effects, such as Pfizer-BioNTech. These include anaphylaxis and myocarditis.³ Moreover, the African population was not adequately represented in RTCs. Therefore, the safety of the vaccines can only be determined by post-market safety surveillance. Given that vaccines are often recommended for healthy individuals, the key to the success of NIPs is public trust in vaccine safety. ⁴ Thus, systematic vaccine safety surveillance is indispensable for ensuring the safety and public trust in vaccines. Safety surveillance is expected to provide additional information on incidence, distribution, and risk factors for expected and unexpected serious and minor AEFIs.⁵ According to the World Health Organization (WHO), all adverse events(AEs) that concern the caregiver and have associated costs and effects should be reported regardless of severity.⁶ The present study aimed to investigate the occurrence of AEFI during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo. By conducting a thorough analysis of AEFI data collected from these campaigns, this study sought to provide valuable insights into the safety profile of vaccines administered. It contributed to the evidence base for future vaccination efforts.

Methods

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

Study Setting and Design

We conducted a prospective follow-up study using an active safety surveillance approach among COVID-19 vaccine recipients in the Democratic Republic of Congo (DRC). As of June 2023, 17.05 million individuals in the DRC have received at least one dose of COVID-19 vaccine. ⁷ The Ministry of Public Health of the DRC, through the Expanded Programme on Immunization (EPI), with the support of Africa Centres for Disease Control and Prevention (Africa CDC) and implementing partners, conducted a two-week Rapid Results Initiative (RRI) COVID-19 mass vaccination campaign. From December 1 to 29, 2023 in Kinshasa province, selected vaccine recipients were recruited for the follow-up. The campaign's primary objective was to accelerate the COVID-19 vaccination efforts and improve the low vaccination coverage in DRC. Africa CDC and EPI conducted COVID-19 vaccine safety surveillance to document AEFI during the campaign. During this mass vaccination campaign in the DRC, two types of COVID-19 vaccines were administered: the Pfizer-BioNTech mRNA vaccine and the Johnson & Johnson (J&J) nonreplicating vector vaccine. The Pfizer-BioNTech vaccine utilizes mRNA technology to train the immune system to recognize the spike protein of the coronavirus.8On the other hand, the J&J vaccine delivers the virus' DNA to host cells using an adenovirus as a delivery vehicle).9

Study participants

The COVID-19 mass vaccination campaign occurred in 159 vaccination sites distributed in 29 health zones of Kinshasa Province. In each vaccination site, 5% of the people vaccinated were

randomly selected for safety surveillance, according to the WHO recommendation⁵. Those participants who received COVID-19 vaccines during the campaign consented to participate in the study and provided a reachable phone number.

Data Collection and Management

We used a structured questionnaire adapted from the WHO safety surveillance tool⁵. The tool captured data on population characteristics such as patient ID, province, profession, sex, and age, as well as vaccine-related information such as batch number, number of doses, type of vaccine, vaccination date, and the record of AEF. The data concerning AEFI included the date of the caller, the date of onset of the event and the type of AEFI. Follow-up calls were made on days 1, 3, 5, 7, 14, 21, and 28 after vaccine administration and data collection forms were used to record information. The AEFI was considered serious in case of an event that results in death, hospitalization, or prolongation of an existing hospitalization, persistent or significant disability or incapacity, congenital anomaly/birth defect, or is life-threatening or is a medically important event or reaction.⁵ Africa CDC recruited and trained a local team of AEFI focal points to conduct follow-up calls to identify and monitor the AEFI. A data collection line listing form with built-in validation rules was used to ensure data quality during data entry.

Data Analysis

The study's primary outcome was the experience of at least one AEFI among those receiving at least one dose of any COVID-19 vaccine used during the vaccination mass campaign. Eight

Adverse Events for Special Interest (AESI) conditions pre-defined for surveillance based on WHO recommendation, including fever, vomiting, headache, muscle pain, joint pain, body aches, persistent pain at the injection site, diarrhea, and chills, were followed and monitored. We dichotomized the number of events as 2 or more coded as one (1) and 0-1 coded as zero (0) for our logistic regression model for the number of AEs 14. The independent variables considered in this analysis included age (dichotomized as <36 years and ≥36 years), sex, type of COVID-19 vaccines, and the number of COVID-19 vaccine doses received. Descriptive statistics were used to summarize socio-demographic characteristics and vaccinerelated information by frequency and proportion for categorical variables and median with interquartile range (IQR) for numerical variables. The cumulative incidence rate of AEFI was provided by proportion along with its respective 95% confidence interval. The multivariate regression models for statistical analysis using the backward-elimination regression approach included all the above-mentioned independent variables. Multicollinearity was assessed by the variance inflation factor (VIF) and the tolerance test (≥0.1). The VIF below ten was considered acceptable to declare lack or absence of multicollinearity. Variables with collinearity were omitted from the models. The goodness of model was assessed by the Hosmer Lemeshow goodness of fit test (P-value >0.05). Multivariable logistic regression models identified factors associated with experiencing AEFI and expressed by adjusted odds ratio (aOR) and its 95% CI. A p-value < 0.05, together with 95%CI, was used to declare statistical significance. Stata IC version 16 (Stata Corp) was used to analyze the data in this study.

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Ethical considerations

After the vaccine was administered, selected participants were informed about the purpose of this surveillance and were asked to willingly participate in this survey. The consent was obtained verbally. The verbal consent was documented on vaccine recipients' follow up form and witnessed by the enumerator. Those who consented provided their phone numbers to enable follow-up calls. The parents' phone numbers were provided for the vaccine recipients under 18. To ensure confidentiality, de-identified data was shared with Africa CDC to analyze the vaccine's safety profile following immunization. Ethical Approval was obtained from the appropriate Institutional Review Board to conduct this survey and publish the findings from this analysis.

Results

Population and Vaccine Characteristics

The analysis included 4766 participants, with a median age of 36 (Interquartile Range [IQR]: 27-

48). More than half (53%) of the participants were females, and more than 70% of respondents

were in the 20—to 49-year age range.

Most participants (94.4%) received the Johnson & Johnson vaccine, and the remaining 5.6% were

vaccinated with the Pfizer vaccine. Those taking their second dose were 0.6%, and 99.4% took

their first dose (Table 1).

Table 1: Population and vaccine characteristics

Variables (N= 4766)	Group	N	% (95%CI)
Sex	Male	2,263	47.48 % (46.06%-48.91%)
Sex	Female	2,503	52.51% (51.09-53.94%)
Type of Vaccine	181	4,509	94.61% (93.93%-95.23%)
Type of Vaccine	Pfizer	256	5. 37% (4.75%-6.05%)
Number of doses	First	4,739	99.43% (99.18%-99.63%)
Number of doses	Second	27	0.57% (0.37%-0.82%)
	<12 years	2	0.04% (0.01-0.15%)
	12-17 years	38	0.78% (0.56%-1.09%)
	18-19 years	171	3.58% (3.08%-4.16%)
Age Groups	20-29 years	1,343	28.18% (26.90%-29.47%)
Age droups	30-39 years	1,236	25.93% (24.69%-27.20%)
	40-49 years	882	18.51% (17.41%-19.63%)
	50-59 years	626	13.13% (12.19%-14.12%)
	60+ years	467	9.79% (8.97%-10.68%)
Seriousness of AEFIs	Serious	6	0.13% (0.05%-0.27%)
SETTOUSTIESS OF AEFIS	Non-serious	4760	99.87% (97.73%-99.95%)

Incidence and Forms of AEFI Reported

Overall, 1131 (23.75%, 95% CI: 22.55% - 24.99%) reported having developed at least one AEFI during the study period. The most frequent forms of AEFI reported (ranging between 1% to 10%) are fever 458(9.61%, 95%CI: 8.88%-10.48%) followed by pain on injection site 429 (9.00%, 95%CI: 8.20%-9.85%), headache 196 (4.11%, 95%CI: 3.57%-4.72%), stiffness 72 (1.51%, 95%CI: 1,18%-1.89%) and myalgia 55(1.15%, 95%CI: 0.87%-1.49%). The less frequent forms (ranging between 0.1% to 1%) include vomiting 24 (0.50%, 95%CI: 0.32%-0.75%), arthralgia 18(0.38%, 95%CI: 0.22%-0.59%), diarrhea 12(0.25%, 0.13%-0.44%), vertigo 12(0.25%.95%CI: 0.13%-0.44%) and chills 10 (0.21%, 95%CI: 0.10%-0.38%). The unusual AEFIs reported (ranging between 0.01% to 0.1%) are heaviness of arm 4 (0.08%, 95%CI: 0.02%-0.21%), gastritis 2 (0.04%, 95%CI: 0.010%-15%), blood pressure 1(0.02%, 95%CI: 0.01%-0.11%)), blurred vision 1 (0.02%, 95%CI: 0.01%-0.11%), burning sensation 1 (0.02%, 95%CI: 0.01%-0.11%) (Figure1)

Figure 1: Frequency of reported AEFIs

Factors Associated with the Incidence of AEFIs

In the multivariable analysis, the occurrence of an AEFI was statistically associated with age and the type of vaccine administered. Incidence of AEFI was higher among Pfizer vaccine recipients (34.38%, 95% CI: 28.57%%-40.54%) versus J&J vaccine recipients (23.15%, 95% CI: 21.92%-24.41%); slightly higher among vaccine recipients aged 36 years and more (25.11%, 95%CI: 23.39%-26.88%) versus those below 36 years of age (22.34%, 95% CI: 20.66%-24.08%). The odds of any AEs were about two times higher in the Pfizer vaccine (aOR, 1.73; 95% CI: 1.31-2.28); p<0.001) as compared to J & J vaccine recipients and 17% higher among the older age group

(aOR, 1.17, 95%CI: 1.02-1.33; p<0.022) at 36 years and more vs. <36 years. No statistical association was found for gender and number of doses (**Table 2**).

Table 2: Factors associated with the incidence of AEFIs

Independent	Group	AEFI	AEFI	% AEFI	aOR (95%CI)	P-value
Variables		(-)	(+)			
	Male	1,908	595	23.77%	1.00 (0.87-1,14)	0.986
Gender	Female	1,726	537	23.70%	1 (Ref)	
	36 Years and +	1,819	610	25.11%	1.17 (1.02-1.34)	0.022*
Age	<36 years	1,815	522	22.34%	1 (Ref)	
	Pfizer	168	88	34.38%	1.73 (1.32-2.28)	0.001*
Type of Vaccine	Johnson &	3,466	1,044	23.15%	1 (Ref)	
	Johnson					
Number of doses	1 st dose	3,613	1,126	23.76%	1.87(0.73-4.79)	0.190
administered	2 nd dose	21	6	22.22%	1 (Ref)	

* Significant factors, p<0.05

Fever was higher for Pfizer vaccine recipients (12.50%, 95%CI; 8.71%-17.18%) than J&J vaccine recipients (9.45%, 95%CI: 4.35%-10.34%). Recipients of the Pfizer vaccine were more likely susceptible to developing fever than recipients of the J&J vaccine (aOR=1.47, 95%CI: 1,02-2.16; p<0.048) (Table 3).

Table 3: Factors Associated with Fever

Independent	Group	Fever(-)	Fever	% Fever	aOR (95%CI)	P-value
Variables			(+)			
Gender	Male	2,255	248	9.91%	1.07 (0.89-1.30)	0.452
	Female	2,053	210	9.28%	1 (Ref)	
Age	36 years and +	2,196	233	9.59%	0.96(0.82-1.20)	0.963
	<36 years	2,112	225	9.63%	1 (Ref)	
Type of Vaccine	Pfizer	224	32	12.5%	1.47(1,002-2.16)	0.048*
	Johnson &	4,084	426	9.45%	1 (Ref)	
	Johnson					

* Significant factors, p<0.05

The proportion of persistent pain at the injection site was higher for Pfizer vaccine recipients (15. 23%, 95%CI: 11.06%-20.23%%) vs J&J vaccine recipients (8.65%, 95%CI: 4.29%-9.51%). Respondents vaccinated with the Pfizer Vaccine had a 76% increased risk of reporting pain at the injection site than those vaccinated with the J&J vaccine (aOR=1.76,95%CI: 1.21-5.56; p<0.003). Respondents aged 36 years and older also had a 36% increased risk of reporting pain at the site of injection compared to those aged below 36 years (aOR=1.36, 95%CI: 1.11-1.66; p<0.003). Although not statistically significant, the incidence of persistent pain at the injection site was higher after the 2nd dose (18.52%, 95%CI 6.30%-38.08%) than the first dose (8.95%, 95%CI: 8.15-%-9.79%) (Table 4)

Table 4: Factors associated with persistent pain at the injection site

Independent Variables	Groups	Pain (-)	Pain	% Injection	aOR (95%CI)	P-Value
			(+)	site pain		
	Male	2,280	223	8.91%	0.97(0.79-1.18)	0.756
Gender	Female	2,057	206	9.10%	1 (Ref)	
Age group	36 Years and	2,181	248	10.21%	1.36(1.11-1.66)	0.003*
	<36 years	2,156	181	7.74%	1 (Ref)	
	Pfizer	217	39	15.23%	1.76(1.21-5.56)	0.003*
Type of Vaccine	Johnson & Johnson	4,120	390	8.65%	1 (Ref)	
Number of doses	1 st dose	4,315	424	8.95%	0.75(0.27-2.12)	0.598
administered	2 nd dose	22	5	18.52%	1 (Ref)	

* Significant factors, p<0.05

Headache was more reported among Pfizer vaccine recipients (9.77%, 95%CI: 6.42%-14.07) than J&J vaccine recipients (3.79%, 95%CI: 3.25%-4.39%), muscle pain was reported by 3.52% (95%CI: 1.62%-6.57%) of Pfizer vaccine recipients vs 1.02% (95%CI; 0.75%-1.35) of J&J vaccine recipients. The more significant proportion of Pfizer vaccine recipients reported two or more symptoms (10.94%, 95%CI: 7.39%-15.41%) than J&J vaccine recipients (4.06%, 95%CI: 3.50%-4.65%). Respondents aged 36 years and more had a 46% increased risk of complaining of 2 side effects or more compared to those aged below 36 years (aOR=1.46, 95%CI: 1.10-1.94; p<0.008).

While all AEs were more predominant in Pfizer than in J&J vaccine, the odds were particularly higher for headache (aOR=2.8, 95%CI: 1.80-4.42; p<0.001) (Table 5), myalgia (aOR=3.79, 95%CI: 1.83-7.84; p<0.001) (Table 6) and reporting two signs or more (aOR=3.02, 95%CI: 1.97-4.63; p<0.001). (Table 7)

221 Table 5: Factors associated with headache

Independent	Groups	Headach	Headac	%	OR (95%CI)	P-Value
Variables		e (-)	he (+)	Headache		
Gender	Male	2,398	105	4.19%	1.05 (0.79-1,40)	0.707
	Female	2,172	91	4.02%	1 (Ref)	
	36 Years and +	2,329	100	4.12%	1.00 (0.75-1.34)	0.970
Age	<36 years	2,241	96	4.11%	1 (Ref)	
	Pfizer	231	25	9.77%	2.82 (1.80-4.42)	0.001*
Type of Vaccine	Johnson & Johnson	4,339	171	3.79%	1 (Ref)	
Number of	1 st dose	4,544	190	4.11%	2.85(0.37-21.93)	0.313
doses	2 nd dose	21	6	3.70%	1 (Ref)	

* Significant factors, p<0.05

224

Table 6: Factors associated with muscle pain

226

Independent						P-
Variables	Groups	Myalgia (-)	Myalgia (+)	% Myalgia	aOR(95%CI)	Value
	Male	2,474	29	1.16%	1.01(0.59-1.73)	0.96
Gender	Female	2,237	26	1.15%	1 (Ref)	
Age	36 years and +	2,398	31	1.28%	1.25(0.74-2.15)	0.401
	<36 years	2,313	24	1.03%	1 (Ref)	
Type of Vaccine	Pfizer	247	9	3.52%	3.79(1.83-7.84)	0.001*
	18 1	4,464	46	1.02%	1 (Ref)	
Number of doses	1 st dose	4,684	55	1.16%	Omitted	
administered	2 nd dose	27	0	0.00%		

* Significant factors, p<0.05

Table 7: Factors associated with the number of signs reported by an individual

Independent	Groups	< 2	2 signs	% 2 signs	aOR(95%CI)	P-value
Variables		signs	and +	and +		
	Female	2,163	100	4.43%	0.99 (0.76-1.32)	0.992
Gender	Male	2,392	111	4.42%	1 (Ref)	
Age	36 Years and +	2,303	126	5.19%	1.46 (1.10-1.94)	0.008*
	<36 years	2,252	85	3.64%	1 (Ref)	

	Pfizer	228	28	10.94%	3.02 (1.97-4.63)	0.001*
Type of Vaccine	Johnson & Johnson	4,327	183	4.06%	1 (Ref)	
Number of	1 st dose	4,529	211	4.43%	3.37 (0.44-25.83)	0.242
doses	2 nd dose	26	1	3.57%	1 (Ref)	
administered						

* Significant factors, p<0.05

Discussion

The clinical trials during the development of COVID-19 vaccines were mainly conducted in developed nations, so they might not optimally represent the safety situation in the African setting. The findings from our safety surveillance analysis indicate that a significant proportion of COVID-19 vaccine recipients experienced AEFIs. Specifically, the study revealed that about a quarter of individuals who received the vaccine reported any AEFIs and the AEFIs were related to the type of vaccines administered and the age of the recipients. This finding is consistent with clinical trials. In the results from the clinical trial on the safety of mRNA vaccines, more mRNA recipients than placebo recipients reported any adverse event (27% and 12%, respectively) or a related adverse event (21% and 5%). There was a slight difference between the first and second dose, with 23.76% (95%CI: 22.55%-24.99%) experiencing AEFIs after receiving the first dose and 22.22% (95%CI: 8.62%-42.26%) after the second. Furthermore, it was observed that a higher proportion of individuals who received the Pfizer vaccine (34.38%, 95% CI: 28.57%%-40.54%) reported AEFIs compared to those who received the J&J vaccine (23.15%, 95% CI: 21.92%-24.41%).

Considerable differences were observed in the trends of AEFIs compared with results from the participant-reporting studies. The UK app study showed that 71.9% (dose 1) and 68.2% (dose 2) reported local side effects. 12 In the US online cohort study, AEs were reported to be 64.9% partially vaccinated and 80.3% fully vaccinated with the mRNA vaccine. 13 The proportion of AEs was generally lower in our study. We can speculate that the difference might be due to potential age differences in the study cohort. In our study, the population mainly comprised of younger individuals (median age of 36 years) compared with the studies mentioned above (54 years; UK study; 59-64 years; US study), contrasting trends of AEFIs and association of age was observed, unlike other studies. Moreover, we did not assess whether participants were pre-medicated before vaccination. A study conducted in Ghana revealed that almost half of the respondents pre-medicated with paracetamol before vaccination.¹⁴ The importance of this factor cannot be ruled out since it may contribute significantly to how an individual's immune system responds to the vaccine. This creates an avenue for further research to determine if this is the case. Another explanation might be that for participant-reporting studies, the vaccinees without AEs might be less motivated to proactively report Zero AEFI, leading to more reports from those who experienced AEs.

Forms of AEFI

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

Findings from this study showed that the most common adverse event experienced among the majority after COVID-19 vaccination included fever (458 cases), pain on injection site (429 cases), headache (196 cases), stiffness (72 cases), and myalgia (55 cases). The adverse events experienced were no different from those experienced across the world.¹⁵ In the Ethiopian study

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

conducted by Jerso et al. on healthcare workers vaccinated against COVID-1916, the most prevalent symptoms experienced in descending order include - pain at the injection site (64.1%), fatigue (35.7%), headache (28.9%), joint pain (26.5%) and muscle pain (21.5%). In the study conducted in Ghana, the prevalence of pain at the injection site also hovered around a similar figure of 65.8%, which was also the most common symptom experienced post-COVID-19 vaccination. The second most common symptom was headache (57.5%), followed by the following—tiredness (55.8%), fever (51.7%), chills (39.6%), and muscle pains (38.3%).14 In our study, pain at the injection site was the second most common symptom after fever. It is, however, difficult to compare those studies to ours because J&J and Pfizer were not the predominant vaccines administered in those studies. However, the running theme seems to be that pain at the injection site was among the first 2 most common adverse events or side effects in all studies mentioned. Although not statistically significant, the occurrence of injection site pain in our study was higher among vaccine recipients of the second dose than those with the first dose (18.5% vs 8.9%). These results corroborate the findings of the clinical trials that revealed that the proportion of almost all AEFIs was higher in recipients of the second dose. 1718 Similar to previous studies, injection site pain and muscle pain were among the most predominant AEs. 19,20

Seriousness of AEFIs

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

In our findings, 6 (0.13%) serious AEs were reported. In the clinical trial on the safety of mRNA vaccines, the incidence of serious adverse events was similar in the vaccine and placebo groups (0.6% and 0.5%, respectively).¹⁷

Factors Associated with AEFIs

Our findings revealed that the vaccine type was the most significant factor that may impact AEs. Pfizer vaccine recipients were significantly associated with greater odds of reporting fever (aOR=1.47, 95%CI: 1,02-2.16; p<0.048), headache (aOR=2.8, 95%CI: 1.80-4.42; p<0.001), injection site pain (aOR=1.76,95%CI:1.21-5.56; p<0.003)), and having more than 2 signs (aOR=3.02, 95%CI: 1.97-4.63; p<0.001), compared to the J&J vaccine recipients. Particularly, Pfizer (an mRNA vaccine) was significantly associated with higher odds of AEs than J&J. These results were consistent with the findings of clinical trials^{17,18} survey-based studies^{13,21,22} and a government-sponsored surveillance study²³. Of the baseline characteristics, female gender was not one of the evident factors associated with AEFIs in this study. This was considerably different from previous findings, which showed that the overall incidence of AEs in women was generally higher than that in men.^{13,21} A notable finding from these studies was that female participants reported menstrual disorders and unexpected vaginal bleeding after mRNA vaccination. Menstrual disorders and unexpected vaginal bleeding should be carefully monitored in future surveys.

Limitations

Our results should be interpreted with caution given the following limitations. First, there might be potential misclassification of outcomes, as AEFIs reported by the participants were not medically reviewed and classification of the AEFI has not been conducted. Secondly, our survey focused only on specific AEFIs using a pre-identified list, limiting the scope and potentially excluding other AEFIs. Thirdly, as we only examined the short-term safety of COVID-19 vaccines, further studies are required to evaluate the long-term AEs. Lastly, this survey did not assess for any pre-existing medical conditions or whether participants were pre-medicated before vaccination.

Conclusion

In conclusion, this survey conducted in Kinshasa (DRC) revealed that approximately 24% of COVID-19 vaccine recipients aged 5–90 years reported AEFIs, and most of AEFIs were mild and transient. Fever, Injection site pain, headache, and muscle pain were the most predominant AEFIs reported by COVID-19 vaccine recipients. We also found that vaccination with the Pfizer vaccine and age of 36 years or more were associated with the incidence of AEFIs. The Pfizer vaccine was significantly associated with greater odds of reporting fever, headache, muscle pain, injection site pain, and more than 2 signs compared to the J&J vaccine. Individuals aged 36 years or more were associated with greater odds of reporting pain at injection site and having more than 2 AEFIs. Further safety surveys monitoring all potential factors are needed to generate more evidence on COVID-19 vaccine safety in an African population. This information will support establishing future vaccination strategies tailored to individuals potentially susceptible to AEFIs.

Acknowledgments

We thank the participants in this study for their great contribution to safety surveillance and the

Ministry of Health for sharing data with Africa CDC to enable this analysis.

References

327

329

- 331 1. WHO. Protocol template to be used as template for observational study protocols: cohort
- event monitoring (CEM) for safety signal detection after vaccination with COVID-19
- vaccines [Internet]. 2021 [cited 2024 Jan 8]. Available from:
- https://www.who.int/publications/i/item/9789240027398
- 335 2. Islam A, Bashir MS, Joyce K, Rashid H, Laher I, Elshazly S. An Update on COVID-19 Vaccine
- Induced Thrombotic Thrombocytopenia Syndrome and Some Management
- Recommendations. Molecules [Internet]. 2021 Aug 2 [cited 2024 Jan 8];26(16). Available
- from: /pmc/articles/PMC8400504/
- 339 3. Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA
- 340 COVID-19 Vaccination | CDC [Internet]. Centers for Disease Control and Prevention. 2021
- [cited 2024 Jan 8]. Available from: https://www.cdc.gov/coronavirus/2019-
- 342 ncov/vaccines/safety/myocarditis.html
- 343 4. World Health Organization. Vaccine Safety Basics | OpenWHO [Internet]. [cited 2024 Jan
- 344 8]. Available from: https://openwho.org/courses/vaccine-safety-basics
- 345 5. World Health Organization. Safety Surveillance Manual Safety Surveillance. Available
- 346 from: Safety Surveillance Manual Safety Surveillance.

347	6.	WHO. Safety Monitoring of Medicinal Products: Reporting Systems For The General Public.
348		2000 [cited 2024 Jan 8];35(3):41–3. Available from:
349		http://www.scopus.com/inward/record.url?eid=2-s2.0-
350		0025317538&partnerID=40&md5=6ff30e08e26b99f08c46a3bb4c28a332
351	7.	Our World in Data. Total number of people who received at least one dose of COVID-19
352		vaccine [Internet]. Our World in Data. 2023 [cited 2024 Jan 8]. Available from:
353		https://ourworldindata.org/grapher/people-vaccinated-covid
354	8.	Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A Single
355		Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and
356		Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity [Internet]. 2020 Oct
357		10 [cited 2024 Jan 8];53(4):724. Available from: /pmc/articles/PMC7392193/
358	9.	Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based
359		vaccines and COVID-19 variants. Le Infez Med [Internet]. 2021 [cited 2024 Jan
360		8];29(3):328–38. Available from: https://pubmed.ncbi.nlm.nih.gov/35146337/
361	10.	Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported
362		From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem [Internet]. 2021
363		Oct 1 [cited 2024 Jan 8];36(4):427. Available from: /pmc/articles/PMC7997788/
364	11.	Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy
365		of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 31 [cited 2024
366		Jan 8];383(27):2603–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33301246/

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and 367 12. 368 SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis [Internet]. 2021 Jul 1 [cited 2024] 369 Jan 8];21(7):939–49. Available from: https://pubmed.ncbi.nlm.nih.gov/33930320/ 370 Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 371 13. Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw open [Internet]. 2021 372 22 Available from: 373 Dec [cited 2024 Jan 9];4(12). https://pubmed.ncbi.nlm.nih.gov/34935921/ 374 Boi-Dsane NAA, Dzudzor B, Alhassan Y, Aheto JMK. Prevalence of common adverse events 375 14. experienced following COVID-19 vaccination and its associated factors in Ghana: Cross-376 sectional study design. Heal Sci reports [Internet]. 2022 Jan 1 [cited 2024 Jan 9];6(1). 377 Available from: https://pubmed.ncbi.nlm.nih.gov/36582625/ 378 Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. 379 15. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of 380 Randomized Clinical Trials. Vaccines [Internet]. 2021 May 1 [cited 2024 Jan 9];9(5). 381 Available from: https://pubmed.ncbi.nlm.nih.gov/34066475/ 382 Jarso G, Gebi W, Abdo M, Lemma M, Abebe E, Lemessa B, et al. Prevalence of COVID-19 383 16. Vaccine Side Effects among Early-Vaccinated Healthcare Workers in Eastern Ethiopia. 384 Ethiop J Health Sci [Internet]. 2022 May 1 [cited 2024 Jan 9];32(3):473. Available from: 385 /pmc/articles/PMC9214739/ 386 17. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy 387

of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 31 [cited 2024 388 389 Jan 9];383(27):2603–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33301246/ 390 18. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2021 Feb 4 [cited 2024 Jan 391 9];384(5):403–16. Available from: https://pubmed.ncbi.nlm.nih.gov/33378609/ 392 393 19. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med [Internet]. 2021 394 16 cited 2024 9];385(12):1078–90. Available from: 395 Sep Jan 396 https://pubmed.ncbi.nlm.nih.gov/34432976/ 397 20. Chen G, Li X, Sun M, Zhou Y, Yin M, Zhao B, et al. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. Front Immunol. 2021 398 May 21;12:669010. 399 Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, et al. Adverse reactions 400 21. to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother 401 [Internet]. 2022 Apr 1 [cited 2024 Jan 9];28(4):576–81. Available 402 from: https://pubmed.ncbi.nlm.nih.gov/35058126/ 403 Valera-Rubio M, Sierra-Torres MI, Castillejo García R, Cordero-Ramos J, López-Márquez 404 22. MR, Cruz-Salgado Ó, et al. Adverse events reported after administration of BNT162b2 and 405 mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based 406 407 study in a Spanish hospital. Expert Rev Vaccines [Internet]. 2022 [cited 2024 Jan 9];21(4):1. Available from: /pmc/articles/PMC8787836/ 408

COVID-19 Vaccines. JAMA [Internet]. 2021 Jun 1 [cited 2024 Jan 9];325(21):2201–2.

Available from: https://jamanetwork.com/journals/jama/fullarticle/2778441




Figure 1: Frequency of reported AEFIs